Background. Staphylococcus aureus is a leading cause of serious healthcareassociated infections, resulting in substantial healthcare system burden. To date, there is no licensed vaccine to prevent invasive S. aureus disease. In this first-in-human study, we evaluated the safety, tolerability and immunogenicity of a single-dose of a 4-antigen S. aureus vaccine (SA4Ag) containing capsular polysaccharide serotypes 5 and 8 (CP5 and CP8) individually conjugated to CRM 197 , a recombinant surface protein clumping factor A (rmClfA), and a recombinant manganese transporter protein C (rP305A).
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Methods. 456 healthy adults in 2 age strata (18 to 49 years; 50 to 64 years) were randomized to receive a single intramuscular injection with one of 3 SA4Ag formulations (fixed doses of 30 µg , and 60 µg rmClfA and either low-[20 µg], mid-[60 µg], or high-[200 µg] dose rP305A) or placebo. Reactogenicity and adverse event data were collected. Functional opsonophagocytic activity (OPA) killing was assayed at multiple time points using CP5-and CP8-expressing clinical S. aureus strains. Antigen-specific immunogenicity was assessed using a fibrinogen binding inhibition (FBI) assay and a 4-plex competitive Luminex ® immunoassay (cLIA). Predefined immunogenicity thresholds were applied to assess the response to each antigen.
Results. SA4Ag was well tolerated with an acceptable safety profile at all rP305A dose levels evaluated. At Day 29, all SA4Ag recipients achieved the CP5 OPA threshold and 96.2-99.0% of vaccine recipients achieved the OPA threshold for CP8. A doseresponse was noted for rP305A with 46.7%, 63.2%, and 82.9% of the low-, mid-, and high-dose rP305A recipients achieving the cLIA threshold, respectively. For both age strata, substantial increases in cLIA geometric mean titers (GMTs) 
